Skip to main content
Erschienen in: Clinical Rheumatology 10/2011

01.10.2011 | Original Article

Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies

verfasst von: Malgorzata E. Krzyszczak, Yi Li, Steven J. Ross, Angela Ceribelli, Edward K. L. Chan, Michael R. Bubb, Eric S. Sobel, Westley H. Reeves, Minoru Satoh

Erschienen in: Clinical Rheumatology | Ausgabe 10/2011

Einloggen, um Zugang zu erhalten

Abstract

Autoantibodies to topoisomerase I (topo I), RNA polymerase III (RNAPIII), centromere, U3RNP/fibrillarin, Th, PM-Scl, and U1RNP found in scleroderma (SSc) are associated with unique clinical subsets. The effects of race and gender on autoantibody prevalence and clinical manifestations were examined. Autoantibodies in sera from 105 SSc (include 75 Caucasian, 24 African-American, 6 others; 89 females and 16 males) were analyzed by immunofluorescence and immunoprecipitation. Clinical information was from database. SSc-related autoantibodies seldom coexist except for anti-topo I and anti-U1RNP. Anti-topo I (35% vs 15%), anti-U3RNP (30% vs 3%, p = 0.0005), and anti-U1RNP (30% vs 13%) were more common in African-Americans vs Caucasians. Anti-centromere (17%) and anti-PM-Scl (only in 8% of female) were found only in Caucasians. In race/gender combination, all three African-American males had anti-topo I (p = 0.04). Anti-U3RNP (35% vs 3%, p = 0.0005) and anti-U1RNP were common in African-American females. In African-American, all nucleolar dominant staining sera had anti-U3RNP; nuclear pattern was topo I (50%), U1RNP (19%), and RNAPIII (13%). In Caucasian, nucleolar was anti-Th (43%) and PM-Scl (29%); nuclear pattern was RNAPIII (29%), topo I (24%), and U1RNP (18%). Anti-topo I, anti-RNAPIII, and anti-U3RNP were associated with diffuse SSc while anti-centromere, anti-Th, and anti-U1 with limited disease. Proximal scleroderma was less common in African-American with anti-topo I (38% vs 91% in Caucasian, p = 0.04). The production of SSc-related autoantibodies is gender and race dependent, and this can be highly relevant in understanding their clinical significance.
Literatur
1.
Zurück zum Zitat Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH (2007) Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 3:721–738PubMedCrossRef Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH (2007) Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 3:721–738PubMedCrossRef
2.
Zurück zum Zitat Satoh M, Vazquez-Del Mercado M, Chan EK (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19:219–228PubMedCrossRef Satoh M, Vazquez-Del Mercado M, Chan EK (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19:219–228PubMedCrossRef
3.
5.
Zurück zum Zitat Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075PubMedCrossRef Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075PubMedCrossRef
6.
Zurück zum Zitat Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44:376–383PubMedCrossRef Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44:376–383PubMedCrossRef
7.
Zurück zum Zitat Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A (2006) Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin Rheumatol 25:542–543PubMedCrossRef Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A (2006) Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin Rheumatol 25:542–543PubMedCrossRef
8.
Zurück zum Zitat Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ (2010) Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality? Autoimmun Rev 9:755–760CrossRef Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ (2010) Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality? Autoimmun Rev 9:755–760CrossRef
9.
Zurück zum Zitat Cavazzana I, Angela C, Paolo A, Stefania Z, Angela T, Franco F (2009) Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 8:580–584PubMedCrossRef Cavazzana I, Angela C, Paolo A, Stefania Z, Angela T, Franco F (2009) Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 8:580–584PubMedCrossRef
10.
Zurück zum Zitat Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
11.
Zurück zum Zitat Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, Reeves WH (1994) Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 94:1981–1989PubMedCrossRef Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, Reeves WH (1994) Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 94:1981–1989PubMedCrossRef
12.
Zurück zum Zitat Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM (1999) Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 42:465–474PubMedCrossRef Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM (1999) Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 42:465–474PubMedCrossRef
13.
Zurück zum Zitat LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed
14.
Zurück zum Zitat Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10:CR615–CR621PubMed Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10:CR615–CR621PubMed
15.
Zurück zum Zitat Welting TJ, Raijmakers R, Pruijn GJ (2003) Autoantigenicity of nucleolar complexes. Autoimmun Rev 2:313–321PubMedCrossRef Welting TJ, Raijmakers R, Pruijn GJ (2003) Autoantigenicity of nucleolar complexes. Autoimmun Rev 2:313–321PubMedCrossRef
16.
Zurück zum Zitat Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778–784PubMedCrossRef Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778–784PubMedCrossRef
17.
Zurück zum Zitat Walker UA, Tyndall A, Czirjak L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Matucci-Cerinic M (2009) Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 68:856–862PubMedCrossRef Walker UA, Tyndall A, Czirjak L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Matucci-Cerinic M (2009) Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 68:856–862PubMedCrossRef
18.
Zurück zum Zitat Medsger TAJr (2001) Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions a textbook of rheumatology, vol 2, 14th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1590–1624 Medsger TAJr (2001) Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions a textbook of rheumatology, vol 2, 14th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1590–1624
19.
Zurück zum Zitat Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EK, Reeves WH et al (2006) Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 54:3051–3056PubMedCrossRef Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EK, Reeves WH et al (2006) Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 54:3051–3056PubMedCrossRef
20.
Zurück zum Zitat Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J (2010) Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 35:276–290PubMedCrossRef Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J (2010) Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 35:276–290PubMedCrossRef
21.
Zurück zum Zitat Dellavance A, Gallindo C, Soares MG, da Silva NP, Mortara RA, Andrade LE (2009) Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology (Oxford) 48:632–637CrossRef Dellavance A, Gallindo C, Soares MG, da Silva NP, Mortara RA, Andrade LE (2009) Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology (Oxford) 48:632–637CrossRef
22.
Zurück zum Zitat Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7–2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33:1822–1828PubMedCrossRef Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7–2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33:1822–1828PubMedCrossRef
23.
Zurück zum Zitat Okano Y, Steen VD, Medsger TAJ (1992) Autoantibody to U3 nucleolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100PubMedCrossRef Okano Y, Steen VD, Medsger TAJ (1992) Autoantibody to U3 nucleolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100PubMedCrossRef
24.
Zurück zum Zitat Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr (1984) Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27:125–131PubMedCrossRef Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr (1984) Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27:125–131PubMedCrossRef
25.
Zurück zum Zitat LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
26.
Zurück zum Zitat Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef
27.
Zurück zum Zitat Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillières Best Pract Res Clin Rheumatol 14:111–124PubMedCrossRef Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillières Best Pract Res Clin Rheumatol 14:111–124PubMedCrossRef
28.
Zurück zum Zitat Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH (1986) Scl 70 antibody—a specific marker of systemic sclerosis. Br J Dermatol 115:393–401PubMedCrossRef Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH (1986) Scl 70 antibody—a specific marker of systemic sclerosis. Br J Dermatol 115:393–401PubMedCrossRef
29.
Zurück zum Zitat Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA (1988) Antinuclear antibodies in scleroderma, mixed connective tissue disease and “primary” Raynaud’s phenomenon. Clin Rheumatol 7:80–86PubMedCrossRef Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA (1988) Antinuclear antibodies in scleroderma, mixed connective tissue disease and “primary” Raynaud’s phenomenon. Clin Rheumatol 7:80–86PubMedCrossRef
30.
Zurück zum Zitat Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34:104–109PubMed Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34:104–109PubMed
31.
Zurück zum Zitat Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Del Papa N, Franceschini F, Guiducci S, Morozzi G et al (2009) Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 36:1464–1469PubMedCrossRef Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Del Papa N, Franceschini F, Guiducci S, Morozzi G et al (2009) Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 36:1464–1469PubMedCrossRef
32.
Zurück zum Zitat Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, Harle JR, Durand JM, Frances Y, Guis S et al (2010) Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma. Eur J Intern Med 21:114–117PubMedCrossRef Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, Harle JR, Durand JM, Frances Y, Guis S et al (2010) Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma. Eur J Intern Med 21:114–117PubMedCrossRef
Metadaten
Titel
Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies
verfasst von
Malgorzata E. Krzyszczak
Yi Li
Steven J. Ross
Angela Ceribelli
Edward K. L. Chan
Michael R. Bubb
Eric S. Sobel
Westley H. Reeves
Minoru Satoh
Publikationsdatum
01.10.2011
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 10/2011
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1751-0

Weitere Artikel der Ausgabe 10/2011

Clinical Rheumatology 10/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.